September 23, 2019 Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a …
Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase
WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney …